REV1 and lymphoma: To further exclude a function of REV1 in tolerating cisplatin-induced lesions in human cells, we performed synergy experiments using multiple doses of cisplatin and REV1i in the p53-KO murine lymphoma, human MCF-7 and HCT116, human prostate cancer cell lines 22RV1 and LNCaP, human ovarian cancer cell SKOV3, MEFs, and human melanoma cell line A375 (see Supplementary table 3A for the concentrations).